Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001410578-24-001766
Filing Date
2024-11-06
Accepted
2024-11-06 16:06:24
Documents
65
Period of Report
2024-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q cldx-20240930x10q.htm   iXBRL 10-Q 1381104
2 EX-31.1 cldx-20240930xex31d1.htm EX-31.1 12797
3 EX-31.2 cldx-20240930xex31d2.htm EX-31.2 12707
4 EX-32.1 cldx-20240930xex32d1.htm EX-32.1 7169
  Complete submission text file 0001410578-24-001766.txt   6163566

Data Files

Seq Description Document Type Size
5 EX-101.SCH cldx-20240930.xsd EX-101.SCH 33301
6 EX-101.CAL cldx-20240930_cal.xml EX-101.CAL 40183
7 EX-101.DEF cldx-20240930_def.xml EX-101.DEF 137611
8 EX-101.LAB cldx-20240930_lab.xml EX-101.LAB 337544
9 EX-101.PRE cldx-20240930_pre.xml EX-101.PRE 239166
68 EXTRACTED XBRL INSTANCE DOCUMENT cldx-20240930x10q_htm.xml XML 1276856
Mailing Address 53 FRONTAGE ROAD SUITE 220 HAMPTON NJ 08827
Business Address 53 FRONTAGE ROAD SUITE 220 HAMPTON NJ 08827 908-200-7500
Celldex Therapeutics, Inc. (Filer) CIK: 0000744218 (see all company filings)

EIN.: 133191702 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 000-15006 | Film No.: 241430907
SIC: 2835 In Vitro & In Vivo Diagnostic Substances
(CF Office: 03 Life Sciences)